Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s338655
Abstract: Abstract In Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M (IgM) gammopathy, aberrant Bruton tyrosine kinase (BTK) signaling has been identified as one mechanism of pathogenesis. For this reason, selective BTK inhibiting… read more here.
Keywords: waldenstr macroglobulinemia; zanubrutinib; zanubrutinib treating; btk ... See more keywords